Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.
Modified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral immunogenic equivalence of three consecutively manufactured MVA p...
Main Authors: | Edgar Turner Overton, Steven J Lawrence, Eva Wagner, Katrin Nopora, Siegfried Rösch, Philip Young, Darja Schmidt, Christian Kreusel, Sonja De Carli, Thomas P Meyer, Heinz Weidenthaler, Nathaly Samy, Paul Chaplin |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5898760?pdf=render |
Similar Items
-
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
by: Richard N Greenberg, et al.
Published: (2016-01-01) -
MVA-BN as monkeypox vaccine for healthy and immunocompromised
by: E.T. Overton, et al.
Published: (2020-12-01) -
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.
by: Richard N Greenberg, et al.
Published: (2015-01-01) -
Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.
by: Richard N Greenberg, et al.
Published: (2015-01-01) -
Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates.
by: Joseph W Golden, et al.
Published: (2012-01-01)